A case of sudden hearing loss during treatment with decitabine for chronic myelomonocytic leukemia

Hee Jun Kim, Eun Kyung Park, In Seok Moon

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Chronic myelomonocytic leukemia (CMML) was initially classified in the category of myelodysplastic syndrome (MDS), but it is now categorized by the 2001 World Health Organization (WHO) classification in a separate nosological group of MDS. Unlike chronic myeloid leukemia (CML), the bone marrow morphology in CMML demonstrates prominent dysplastic changes in at least two of the three myeloid lineages. A 73-year-old male patient was brought to division of hematology for evaluation of leukocytosis. He was diagnosed with CMML and treated with decitabine. The hearing impairment had arisen during the third cycle of decitabine. To our knowledge, this is the first case that idiopathic sudden hearing loss (SHL) occured in CMML patients during treatment with decitabine.

Original languageEnglish
Pages (from-to)E1-E4
JournalChinese Journal of Cancer Research
Volume26
Issue number1
DOIs
Publication statusPublished - 2014 Feb

Fingerprint

decitabine
Leukemia, Myelomonocytic, Chronic
Sudden Hearing Loss
Myelodysplastic Syndromes
Leukocytosis
Hematology
Therapeutics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hearing Loss
Bone Marrow

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{2ea453a6fc51485eb236f6845ceb1880,
title = "A case of sudden hearing loss during treatment with decitabine for chronic myelomonocytic leukemia",
abstract = "Chronic myelomonocytic leukemia (CMML) was initially classified in the category of myelodysplastic syndrome (MDS), but it is now categorized by the 2001 World Health Organization (WHO) classification in a separate nosological group of MDS. Unlike chronic myeloid leukemia (CML), the bone marrow morphology in CMML demonstrates prominent dysplastic changes in at least two of the three myeloid lineages. A 73-year-old male patient was brought to division of hematology for evaluation of leukocytosis. He was diagnosed with CMML and treated with decitabine. The hearing impairment had arisen during the third cycle of decitabine. To our knowledge, this is the first case that idiopathic sudden hearing loss (SHL) occured in CMML patients during treatment with decitabine.",
author = "Kim, {Hee Jun} and Park, {Eun Kyung} and Moon, {In Seok}",
year = "2014",
month = "2",
doi = "10.3978/j.issn.1000-9604.2014.01.05",
language = "English",
volume = "26",
pages = "E1--E4",
journal = "Chinese Journal of Cancer Research",
issn = "1000-9604",
publisher = "Beijing Institute for Cancer Research",
number = "1",

}

A case of sudden hearing loss during treatment with decitabine for chronic myelomonocytic leukemia. / Kim, Hee Jun; Park, Eun Kyung; Moon, In Seok.

In: Chinese Journal of Cancer Research, Vol. 26, No. 1, 02.2014, p. E1-E4.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A case of sudden hearing loss during treatment with decitabine for chronic myelomonocytic leukemia

AU - Kim, Hee Jun

AU - Park, Eun Kyung

AU - Moon, In Seok

PY - 2014/2

Y1 - 2014/2

N2 - Chronic myelomonocytic leukemia (CMML) was initially classified in the category of myelodysplastic syndrome (MDS), but it is now categorized by the 2001 World Health Organization (WHO) classification in a separate nosological group of MDS. Unlike chronic myeloid leukemia (CML), the bone marrow morphology in CMML demonstrates prominent dysplastic changes in at least two of the three myeloid lineages. A 73-year-old male patient was brought to division of hematology for evaluation of leukocytosis. He was diagnosed with CMML and treated with decitabine. The hearing impairment had arisen during the third cycle of decitabine. To our knowledge, this is the first case that idiopathic sudden hearing loss (SHL) occured in CMML patients during treatment with decitabine.

AB - Chronic myelomonocytic leukemia (CMML) was initially classified in the category of myelodysplastic syndrome (MDS), but it is now categorized by the 2001 World Health Organization (WHO) classification in a separate nosological group of MDS. Unlike chronic myeloid leukemia (CML), the bone marrow morphology in CMML demonstrates prominent dysplastic changes in at least two of the three myeloid lineages. A 73-year-old male patient was brought to division of hematology for evaluation of leukocytosis. He was diagnosed with CMML and treated with decitabine. The hearing impairment had arisen during the third cycle of decitabine. To our knowledge, this is the first case that idiopathic sudden hearing loss (SHL) occured in CMML patients during treatment with decitabine.

UR - http://www.scopus.com/inward/record.url?scp=84901397595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901397595&partnerID=8YFLogxK

U2 - 10.3978/j.issn.1000-9604.2014.01.05

DO - 10.3978/j.issn.1000-9604.2014.01.05

M3 - Article

AN - SCOPUS:84901397595

VL - 26

SP - E1-E4

JO - Chinese Journal of Cancer Research

JF - Chinese Journal of Cancer Research

SN - 1000-9604

IS - 1

ER -